Combination Treatment of Intravitreal Ranibizumab, Focal/Grid Laser and Panretinal Photocoagulation in Patients With Diabetic Macula Edema

NCT02131350 — Phase 4, Completed, 40 participants, Shinshu University

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  
RegistryNCT02131350
StatusCompleted
PhasePhase 4
Study typeInterventional; na, single group, masking: none, treatment
Enrollment40 (Actual)
SponsorShinshu University (Other)
ConditionsDiabetic Macula Edema
InterventionsPhotocoagulation, Ranibizumab (Procedure, drug)
Datesstart 2014-04-01, primary completion 2017-03-01, completion 2018-03-01, first posted 2014-05-06, last updated 2018-09-07
Locations1 site in Japan

Related Papers Related Patents Related Grants Related Experts
All trials for Diabetic Macula Edema All trials of Photocoagulation All trials of Ranibizumab

-Summary

The purpose of this study is to evaluate the mean gain in best corrected visual acuity and the number of intravitreal ranibizumab (IVR) injections under the combination treatment of IVR, focal/grid laser and panretinal photocoagulation. Our hypothesis is that suitable photocoagulation decreases the number of IVR injections.

Expand all sections  ·  Collapse all

+Arms and interventions

ArmTypeInterventionsDescription
Ranibizumab with PhotocoagulationExperimentalProcedure: Photocoagulation; Drug: Ranibizumab
  • Photocoagulation (Procedure): Photocoagulation include focal/grid laser and/or panretinal photocoagulation
  • Ranibizumab (Drug)

+Outcome measures

Primary outcomes

  • best corrected visual acuity [every month, up to 36 months]: Best corrected visual acuity is measured with Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart and analysed.

+Eligibility

Sex: All, ages: 20 Years to any

Inclusion Criteria:

* stable medication for the management of diabetes within 3 months
* visual impairment due to focal or diffuse diabetic macula edema
* decreased vision due to diabetic macula edema and not other causes

Exclusion Criteria:

* concomitant conditions in the study eye that could prevent the improvement in VA on the study
* active intraocular inflammation or infection in either eye
* uncontrolled glaucoma in either eye
* treatment with antiangiogenic drugs in the study eye within 3 months
* history of stroke and uncontrolled hypertension

+Locations (1)

FacilityCityCountryStatus
Department ou Ophthalmology Shinshu University School of MedicineMatsumoto, NaganoJapan